ArticleJournal of affective disorders2020
Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes.
Article in Journal of affective disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 55 citations in OpenAlex.
- Metabolic Effects of Healing Touch During Cervical Cancer Treatment: An Exploratory Analysis.Integrative cancer therapiesTrial
- Postmortem metabolomics as a window into the agonal phase of death: a comparison between opioid intoxications and hangings.International journal of legal medicine · 2026Article
- MS-based metabolic profiling in serum for bipolar disorder.Metabolic brain disease · 2026Article
- Editorial: Recognizing Atypical Depression in Youth: Advancing Precision Diagnosis.Journal of the American Academy of Child and Adolescent Psychiatry · 2026Article
- Carnitine dysregulation in diabetic kidney disease: from pathogenic mechanism to precision biomarker.Journal of translational medicine · 2026Review
- Acylcarnitines in Cancer Metabolism: Mechanistic Insights and Stratification Potential.Cancers · 2026Review
- [Gender differences in acylcarnitine metabolism among patients with depression disorder].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025Article
- Blood Plasma Lipid Alterations Differentiating Psychotic and Affective Disorder Patients.Biomolecules · 2025Article
- Validated metabolomic biomarkers in psychiatric disorders: a narrative review.Molecular medicine (Cambridge, Mass.) · 2025Review
- Insomnia, Cognitive Impairment, or a Combination of Both, Alter Lipid Metabolism Due to Changes in Acylcarnitine Concentration in Older Persons.Metabolites · 2025Article
- The Restoration of Energy Pathways Indicates the Efficacy of Ketamine Treatment in Depression: A Metabolomic Analysis.CNS neuroscience & therapeutics · 2025Article
- Serum Lipidome Change in Japanese Patients with Major Depressive Disorder: A Real-World Exploratory Study.Neuropsychiatric disease and treatment · 2025Article
- MADD-like pattern of acylcarnitines associated with sertraline use.Molecular genetics and metabolism reports · 2024Article
- Acylcarnitines are associated with lower depressive symptomatology in a mainland puerto rican cohort.Metabolomics : Official journal of the Metabolomic Society · 2024Article
- Exploring the Effects of Different Drying Methods on Related Differential Metabolites ofPlants (Basel, Switzerland) · 2024Article
- Spatial Heterogeneity of Brain Lipids in SIV-Infected Macaques Treated with Antiretroviral Therapy.Journal of the American Society for Mass Spectrometry · 2024Article
- Metabolic features of treatment-refractory major depressive disorder with suicidal ideation.Translational psychiatry · 2023Article
- Recent Progress in Mass Spectrometry-Based Metabolomics in Major Depressive Disorder Research.Molecules (Basel, Switzerland) · 2023Review
- Metabolomic disorders: confirmed presence of potentially treatable abnormalities in patients with treatment refractory depression and suicidal behavior.Psychological medicine · 2023Article
- Cerebrospinal fluid metabolite alterations in patients with different etiologies, diagnoses, and prognoses of disorders of consciousness.Brain and behavior · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 8 institutions in 3 countries.
Funding
Abstract
backgroundAcylcarnitines have important functions in mitochondrial energetics and β-oxidation, and have been implicated to play a significant role in metabolic functions of the brain. This retrospective study examined whether plasma acylcarnitine profiles can help biochemically distinguish the three phenotypic subtypes of major depressive disorder (MDD): core depression (CD+), anxious depression (ANX+), and neurovegetative symptoms of melancholia (NVSM+).
methodsDepressed outpatients (n = 240) from the Mayo Clinic Pharmacogenomics Research Network were treated with citalopram or escitalopram for eight weeks. Plasma samples collected at baseline and after eight weeks of treatment with citalopram or escitalopram were profiled for short-, medium- and long-chain acylcarnitine levels using AbsoluteIDQ®p180-Kit and LC-MS. Linear mixed effects models were used to examine whether acylcarnitine levels discriminated the clinical phenotypes at baseline or eight weeks post-treatment, and whether temporal changes in acylcarnitine profiles differed between groups.
resultsCompared to ANX+, CD+ and NVSM+ had significantly lower concentrations of short- and long-chain acylcarnitines at both baseline and week 8. In NVSM+, the medium- and long-chain acylcarnitines were also significantly lower in NVSM+ compared to ANX+. Short-chain acylcarnitine levels increased significantly from baseline to week 8 in CD+ and ANX+, whereas medium- and long-chain acylcarnitines significantly decreased in CD+ and NVSM+.
conclusionsIn depressed patients treated with SSRIs, β-oxidation and mitochondrial energetics as evaluated by levels and changes in acylcarnitines may provide the biochemical basis of the clinical heterogeneity of MDD, especially when combined with clinical characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.